RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Burzynski Research Institute Stock

Burzynski Research Institute Stocks 2024

Burzynski Research Institute Stocks

131.45 M

Ticker

BZYR

ISIN

US1231591058

WKN

A0CA3Q

In 2024, Burzynski Research Institute had 131.45 M outstanding stocks, a 0% change from the 131.45 M stocks in the previous year.

The Burzynski Research Institute Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2024131.45
2023131.45
2022131.45
2021131.45
2020131.45
2019131.45
2018131.45
2017131.45
2016131.45
2015131.45
2014131.45
2013131.45
2012131.45
2011131.44
2010131.39
2009131.39
2008131.39
2007131.39

Burzynski Research Institute shares outstanding

The number of shares was Burzynski Research Institute in 2023 — This indicates how many shares 131.448 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Burzynski Research Institute earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Burzynski Research Institute's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Burzynski Research Institute’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Burzynski Research Institute's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Burzynski Research Institute Aktienanalyse

What does Burzynski Research Institute do?

The Burzynski Research Institute Inc is a company based in Houston, Texas, that specializes in the development of cancer treatments. The company was founded in 1976 by Polish physician Stanislaw R. Burzynski, who began his first research on tumor cells. Burzynski made a promising discovery: He identified a group of chemical compounds that he referred to as "Antineoplastons" and described them as effective cancer-fighting agents. One of his key hypotheses was that cancer cells in the body develop due to a malfunction in the normal body's mechanism for combating cancer cells. He therefore developed a therapy that aims to support and enhance this mechanism in the body that normally fights cancer. Burzynski founded the Burzynski Research Institute to further develop his research and therapy. The company's business model is based on the clinical development, patenting, and marketing of cancer treatment methods that rely on the use of Antineoplastons as a central active ingredient. An essential part of the institute's work is collaborating with regulatory authorities such as the US Food and Drug Administration (FDA) to obtain approval for these therapies. The company has obtained several approvals for clinical trials with its cancer treatment technology, including an approval in 2003 for a clinical trial on children with brainstem cancer. The Burzynski Research Institute specializes in various types of cancer treatment, including brain tumors, breast cancer, prostate cancer, and lung cancer. The company also utilizes several different types of Antineoplastons, including phenylacetate, phenylbutyrate, and O-(chloroacetyl)carboxy-phenylglycine. In addition to cancer therapy, the institute also develops other medical products. For example, the institute offers a product called "Emu oil," which is a natural pain-relieving and anti-inflammatory oil. These products are mostly sold directly to patients and are typically not the main source of revenue for the company. The Burzynski Research Institute is not without controversy. There are critics who argue that the company lacks sufficient scientific evidence to prove the effectiveness of their cancer treatment methods. Others have criticized the high prices charged by the company for their treatments. Despite these criticisms, the Burzynski Research Institute has continued its work and further developed its cancer treatment technology, with the aim of finding new and effective ways to combat cancer. The company has also published several books and videos to raise awareness of its work and goals. Overall, the company can be considered a leading, albeit controversial, player in the field of cancer research and therapy. Its products and treatment approaches offer hope and solutions for many cancer patients, but there are still many questions and challenges to be addressed in this important area of medical research. Burzynski Research Institute ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Burzynski Research Institute's Shares Outstanding

Burzynski Research Institute's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Burzynski Research Institute’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Burzynski Research Institute’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Burzynski Research Institute’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Burzynski Research Institute stock

How many stocks are there of Burzynski Research Institute?

The current number of stocks of Burzynski Research Institute is 131.45 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Burzynski Research Institute are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Burzynski Research Institute evolved in recent years?

The number of shares of Burzynski Research Institute has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Burzynski Research Institute as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Burzynski Research Institute?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Burzynski Research Institute pay?

Over the past 12 months, Burzynski Research Institute paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Burzynski Research Institute is expected to pay a dividend of 0 USD.

What is the dividend yield of Burzynski Research Institute?

The current dividend yield of Burzynski Research Institute is .

When does Burzynski Research Institute pay dividends?

Burzynski Research Institute pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Burzynski Research Institute?

Burzynski Research Institute paid dividends every year for the past 0 years.

What is the dividend of Burzynski Research Institute?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Burzynski Research Institute located?

Burzynski Research Institute is assigned to the 'Health' sector.

Wann musste ich die Aktien von Burzynski Research Institute kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Burzynski Research Institute from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Burzynski Research Institute pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Burzynski Research Institute in the year 2023?

In the year 2023, Burzynski Research Institute distributed 0 USD as dividends.

In which currency does Burzynski Research Institute pay out the dividend?

The dividends of Burzynski Research Institute are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Burzynski Research Institute

Our stock analysis for Burzynski Research Institute Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Burzynski Research Institute Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.